

## DAFTAR PUSTAKA

- Abd-Elsalam, S. *et al.* (2022) ‘Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial’, *American Journal of Tropical Medicine and Hygiene*, 106(3), pp. 886–890. Available at: <https://doi.org/10.4269/ajtmh.21-0606>.
- Ahn, D.G. *et al.* (2020) ‘Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)’, *Journal of Microbiology and Biotechnology*. Korean Society for Microbiology and Biotechnology, pp. 313–324. Available at: <https://doi.org/10.4014/jmb.2003.03011>.
- Amber L. Mueller, Maeve S. McNamara and David A. Sinclair (2020) ‘Why does COVID-19 disproportionately affect older people?’, *AGING*, 12(10).
- Beigel, J.H. *et al.* (2020) ‘Remdesivir for the Treatment of Covid-19 — Final Report’, *New England Journal of Medicine*, 383(19), pp. 1813–1826. Available at: <https://doi.org/10.1056/nejmoa2007764>.
- Bohn, M.K. *et al.* (2020) ‘Pathophysiology of COVID-19: Mechanisms underlying disease severity and progression’, *Physiology*. American Physiological Society, pp. 288–301. Available at: <https://doi.org/10.1152/physiol.00019.2020>.
- Burhan, E. *et al.* (2020) *PEDOMAN TATALAKSANA COVID-19 Edisi 4*.
- Cai, Qingxian *et al.* (2020) ‘Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study’, *Engineering*, 6(10), pp. 1192–1198. Available at: <https://doi.org/10.1016/j.eng.2020.03.007>.
- Çalik Başaran, N. *et al.* (2021) ‘Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU’, *Turkish Journal of Medical Sciences*, 51(2), pp. 411–420. Available at: <https://doi.org/10.3906/sag-2006-173>.
- Damayanti, H. *et al.* (2021) ‘The Effectiveness and Safety of Favipiravir in COVID-19 Hospitalized Patients at Tertiary Referral Hospital, Bali, Indonesia’, *Kesmas*, 16(4), pp. 289–297. Available at: <https://doi.org/10.21109/kesmas.v16i4.5433>.

- Deb, S. *et al.* (2021) ‘Adme and pharmacokinetic properties of remdesivir: Its drug interaction potential’, *Pharmaceuticals*. MDPI. Available at: <https://doi.org/10.3390/ph14070655>.
- Dewi Riptasari, R., Abdul Rahem, A. and Purnamayanti, A. (2022) ‘PERBANDINGAN KEBERHASILAN TERAPI ANTIVIRUS FAVIPIRAVIR DAN REMDESIVIR PADA PASIEN COVID-19 DI RSUD dr. DORIS SYLVANUS’, *Jurnal Surya Medika*, 8(1), pp. 125–128.
- Du, Y.X. and Chen, X.P. (2020) ‘Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection’, *Clinical Pharmacology and Therapeutics*. Nature Publishing Group, pp. 242–247. Available at: <https://doi.org/10.1002/cpt.1844>.
- Dyussenbayev, A. (2017) ‘Age Periods Of Human Life’, *Advances in Social Sciences Research Journal*, 4(6). Available at: <https://doi.org/10.14738/assrj.46.2924>.
- Gordon, C.J. *et al.* (2020) ‘Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency’, *Journal of Biological Chemistry*. American Society for Biochemistry and Molecular Biology Inc., pp. 6785–6797. Available at: <https://doi.org/10.1074/jbc.RA120.013679>.
- Gralinski, L.E. and Menachery, V.D. (2020) ‘Return of the coronavirus: 2019-nCoV’, *Viruses*. MDPI AG. Available at: <https://doi.org/10.3390/v12020135>.
- Grein, J. *et al.* (2020) ‘Compassionate Use of Remdesivir for Patients with Severe Covid-19’, *New England Journal of Medicine*, 382(24), pp. 2327–2336. Available at: <https://doi.org/10.1056/nejmoa2007016>.
- Hachfi, W., ben Lasfar, N. and Wissem Hachfi, C. (2020) *COVID-19: Main therapeutic options, LA TUNISIE MEDICALE*.
- Hamdi M.Nur, A., Muflihah, H. and Ary Lantika, U. (2022) ‘Hubungan antara Pemberian Remdesivir dan Durasi Rawat Inap Dibandingkan Favipiravir pada Pasien Covid-19’, *Bandung Conference Series: Medical Science*, 2(1). Available at: <https://doi.org/10.29313/bcsms.v2i1.755>.

- Harrison, A.G., Lin, T. and Wang, P. (2020) ‘Mechanisms of SARS-CoV-2 Transmission and Pathogenesis’, *Trends in Immunology*. Elsevier Ltd, pp. 1100–1115. Available at: <https://doi.org/10.1016/j.it.2020.10.004>.
- Jean, S.S., Lee, P.I. and Hsueh, P.R. (2020) ‘Treatment options for COVID-19: The reality and challenges’, *Journal of Microbiology, Immunology and Infection*. Elsevier Ltd, pp. 436–443. Available at: <https://doi.org/10.1016/j.jmii.2020.03.034>.
- Jin, Z. *et al.* (2013) ‘The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-Triphosphate towards Influenza A Virus Polymerase’, *PLoS ONE*, 8(7). Available at: <https://doi.org/10.1371/journal.pone.0068347>.
- Joshi, S. *et al.* (2021) ‘Role of favipiravir in the treatment of COVID-19’, *International Journal of Infectious Diseases*. Elsevier B.V., pp. 501–508. Available at: <https://doi.org/10.1016/j.ijid.2020.10.069>.
- Kementerian Kesehatan Republik Indonesia (2022) *Situasi Terkini Perkembangan COVID-19*. Jakarta. Available at: <https://covid19.who.int/data>.
- Khairi Lubis, I. (2017) ‘Analisis Length Of Stay (Los) Berdasarkan Faktor Prediktor Pada Pasien DM Tipe II di RS PKU Muhammadiyah Yogyakarta’, *Jkesvo (Jurnal Kesehatan Vokasional)*, 2(2).
- Kumar, M. and al Khodor, S. (2020) ‘Pathophysiology and treatment strategies for COVID-19’, *Journal of Translational Medicine*. BioMed Central Ltd. Available at: <https://doi.org/10.1186/s12967-020-02520-8>.
- Łagocka, R. *et al.* (2021) ‘Favipiravir in therapy of viral infections’, *Journal of Clinical Medicine*. MDPI, pp. 1–16. Available at: <https://doi.org/10.3390/jcm10020273>.
- Lamb, Y.N. (2020) ‘Remdesivir: First Approval’, *Drugs*, 80(13), pp. 1355–1363. Available at: <https://doi.org/10.1007/s40265-020-01378-w>.
- Lu, R. *et al.* (2020) ‘Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding’, *The Lancet*, 395(10224), pp. 565–574. Available at: [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8).

- Mansoor A, Mahabadi N. Volume of Distribution. [Updated 2022 Jul 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK545280/>
- Marliana, L. and Marliani, L. (2021) ‘Analisis Perbandingan Lama Rawat Inap Pasien Terdiagnosis Covid-19 Antara Pemberian Terapi’, *Jurnal Sosial dan Sains*, 1(11). Available at: <http://sosains.greenvest.co.id>.
- McFee, R.B. (2020) ‘COVID-19: Therapeutics and interventions currently under consideration’, *Disease-a-Month*. Mosby Inc. Available at: <https://doi.org/10.1016/j.disamonth.2020.101058>.
- Mudenda, S. *et al.* (2020) ‘Self-medication and its Consequences during & after the Coronavirus Disease 2019 (COVID-19) Pandemic: A Global Health Problem’, *European Journal of Environment and Public Health*, 5(1), p. em0066. Available at: <https://doi.org/10.29333/ejeph/9308>.
- Negru, P.A. *et al.* (2022a) ‘Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir’, *Biomedicine and Pharmacotherapy*. Elsevier Masson s.r.l. Available at: <https://doi.org/10.1016/j.biopha.2022.112700>.
- Negru, P.A. *et al.* (2022b) ‘Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir’, *Biomedicine and Pharmacotherapy*. Elsevier Masson s.r.l. Available at: <https://doi.org/10.1016/j.biopha.2022.112700>.
- Poltronieri, P., Sun, B. and Mallardo, M. (2015) *RNA Viruses: RNA Roles in Pathogenesis, Coreplication and Viral Load, Current Genomics*.
- Price G, Patel DA. Drug Bioavailability. [Updated 2022 Jun 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557852/>
- Sangawa, H. *et al.* (2013) ‘Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase’, *Antimicrobial Agents and Chemotherapy*, 57(11), pp. 5202–5208. Available at: <https://doi.org/10.1128/AAC.00649-13>.

- Simonis, A. *et al.* (2021) ‘A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2’, *EMBO Molecular Medicine*, 13(1). Available at: <https://doi.org/10.15252/emmm.202013105>.
- Singh, A.K. *et al.* (2020) ‘Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies’, *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*, 14(4), pp. 641–648. Available at: <https://doi.org/10.1016/j.dsx.2020.05.018>.
- Suryadi, A. (2017) ‘SISTEM PENDUKUNG KEPUTUSAN PENETAPAN PELAYANAN KUNJUNGAN PASIEN RAWAT INAP DAN RAWAT JALAN PADA UNIT GAWAT DARURAT’, *Jurnal Ilmiah Rekam Medis dan Informatika Kesehatan*, 7.
- Susilo, A. *et al.* (2020) *TINJAUAN PUSTAKA*, *Jurnal Penyakit Dalam Indonesia* |. Available at: <https://www.ncbi.nlm.nih.gov/nucore/>.
- Taslem Mourosi, J., Anwar, S. and Hosen, M.J. (2022) ‘The sex and gender dimensions of COVID-19: A narrative review of the potential underlying factors’, *Infection, Genetics and Evolution*. Elsevier B.V. Available at: <https://doi.org/10.1016/j.meegid.2022.105338>.
- Udwadia, Z.F. *et al.* (2021) ‘Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial’, *International Journal of Infectious Diseases*, 103, pp. 62–71. Available at: <https://doi.org/10.1016/j.ijid.2020.11.142>.
- Wang, Yeming *et al.* (2020) ‘Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial’, *The Lancet*, 395(10236), pp. 1569–1578. Available at: [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9).
- Warren, T.K. *et al.* (2016) ‘Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys’, *Nature*, 531(7594), pp. 381–385. Available at: <https://doi.org/10.1038/nature17180>.
- WHO Solidarity Trial Consortium (2021) ‘Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results’, *New England Journal of*

- Medicine*, 384(6), pp. 497–511. Available at: <https://doi.org/10.1056/NEJMoa2023184>.
- Wiersinga, W.J. *et al.* (2020) ‘Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review’, *JAMA - Journal of the American Medical Association*. American Medical Association, pp. 782–793. Available at: <https://doi.org/10.1001/jama.2020.12839>.
- Williamson, B.N. *et al.* (2020) ‘Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2’, *Nature*, 585(7824), pp. 273–276. Available at: <https://doi.org/10.1101/2020.04.15.043166>.
- World Health Organization (2022) *Guideline Therapeutics and COVID-19: living guideline*. Available at: <http://apps.who.int/bookorders>.
- Yamamura, H. *et al.* (2020) ‘Effect of favipiravir and an anti-inflammatory strategy for COVID-19’, *Critical Care*. BioMed Central. Available at: <https://doi.org/10.1186/s13054-020-03137-5>.
- Yetmar, Z.A. *et al.* (2020) ‘Inpatient Care of Patients with COVID-19: A Guide for Hospitalists’, *American Journal of Medicine*. Elsevier Inc., pp. 1019–1024. Available at: <https://doi.org/10.1016/j.amjmed.2020.03.041>.
- Yuki, K., Fujiogi, M. and Koutsogiannaki, S. (2020) ‘COVID-19 pathophysiology: A review’, *Clinical Immunology*. Academic Press Inc. Available at: <https://doi.org/10.1016/j.clim.2020.108427>.